Halozyme wins court order to block Merck’s injected Keytruda in select European markets
Halozyme said the ruling covers eight markets and leaves Merck’s intravenous Keytruda available to patients.
- On Wednesday, a Dutch patent court in The Hague ordered Merck to halt the manufacture and sale of Keytruda SC in eight European markets, ruling the drug infringes on a Halozyme patent.
- The decision stems from Halozyme's claim that Merck's injectable Keytruda SC infringes its EP 2,797,622 patent, which covers technology enabling rapid, high-volume subcutaneous drug delivery.
- Keytruda SC accounted for $463 million of total Keytruda sales in the second quarter, yet patients retain access to the original intravenous formulation, which remains unaffected by the injunction.
- Mark Snyder, Chief Legal Officer of Halozyme, said, "We're very pleased the Dutch court recognized the validity and infringement of Halozyme's MDASE patent," noting the ruling halts Merck's European launch.
- Following a preliminary injunction in Germany on December 4, 2025, Halozyme continues its global enforcement strategy, including pending patent litigation against Merck in U.S. federal district court.
12 Articles
12 Articles
Merck & MSD’s subcutaneous (SC) formulation of the immuno-oncology drug Keytruda has been held up by a European patent dispute. As Keytruda SC utilizes Alteogen’s subcutaneous formulation conversion technology, ‘ALT-B4,’ this ruling is expected to become a variable affecting Alteogen’s sales milestones and future royalty income if it leads to delays in European sales. On the 7th (local time), the U.S. biotech company Halozyme [registered] in the…
The Daily Advance
PR NewswireHalozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets
SAN DIEGO, Oct. 7, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") announced today that the specialized Dutch patent court of the Hague has found Merck to be infringing one of its MDASE patents, EP 2,797,622…
Coverage Details
Bias Distribution
- 88% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
